



CNS Pharmacology



Website




Videos

CNS PHARMACOLOGY / PATHOLOGY

Neurohumoral Transmission - Transfer of a nerve impulse from presynaptic to postsynaptic target by means of an endogenous humoral agent (NTs)

• Electrochemical Signaling -



Neurotransmitter: - are the endogenous chemicals that transmit signals across a synapse from one neuron to another neuron or target cells and regulate the physiology of postsynaptic cells. **Criteria for NTs** -

- ① Should be present on Nerve end on Synaptic Vesicle
- ② should be release on stimulation of the nerve
- ③ Metabolic enzyme for NT should also present on same neuron
- ④ Every NT has specific target Receptor

• Types of NTs -

1. **Amino acid** - (i) Excitatory - Glutamate, Aspartate
(ii) Inhibitory → GABA, Glycine
2. **Amines** - Dopamine, Nor-Ep., Serotonin (SHT)

3. **Peptides** - Vasopressin, Somatostatin, Neurensin, Enkephalines, Endorphine, Dynorphin

4. **Others** - Acetyl cholin, Nitric oxide, Histamine

Neuropeptides → Neuromodulators


→ Sub P, Neuropeptide Y, VIP, enkephalin

NTs & Specific Role in CNS


NTs	Function	Disorders
Dopamine (D ₁ to D ₅ R)	Extrapyramidal Effect Behavioral - ↓ Prolactin Sec CTZ Stimulat ⁿ Control GH Sec	Parkinson Psychosis Galactorrhoea Vomiting Acromegaly
SHT (5HT ₁ -5HT ₇)	Mood, behavioral, Temp, pain, etc	Mania Depression Hallucination
GABA (GABA _A -GABA _B)	Inhibitory NT (→) CNS activity	Anxiety, Seizure, Hypnotic-sedative
Glycine (GR)	↓ CNS activity	↓ Hyper-reflexia
Glutamate (NMDA)	Excitatory NT	Epilepsy
Nor-Ep	Reward System, mood	Depression, mania
Ach	Behavioral, memory EPS	Alzheimer Parkinson

NEUROTRANSMITTER METABOLISM


Amino Acids




Biogenic Amines




→ Metabolised by - **MAO & COMT (ANS)**




Histamine



Acetylcholine -



Nitric Oxide (NO)




PC

Pharmacology Concepts
By Rajesh Choudhary

GABA RECEPTOR PHARMACOLOGY

GABA - γ -Amino Butyric acid (Major Inhibitory NT)




GAT - x - Tigablin, GABA-Transaminase - Vigabatrin

Receptors - $GABA_A R$, $GABA_B R$, $GABA_C R$

GABA_A Receptor

- * Ionotropic / Ligand Gated ion channel (Cl⁻) - Hyperpolarize
- # Effect - IPSP (Inhibitory post synaptic potential) - \downarrow -70mV
- # Structure \rightarrow Pentameric Transmembrane Receptor having - 5-Subunit ($\beta_2\alpha_1\beta_2\alpha_1\gamma_2$) \rightarrow Anticlock
- # Subunits - α (1-6), β (1-3), γ (1-3), δ , ϵ , π , θ , ϕ (1-3) \rightarrow $GABA_C R$
- # Distribution: - CNS, Placenta, Immune cells, Liver, Endocrine tissue




- GABA Agonist \rightarrow GABA, Muscimol, Gaboxadol, Isoguvacsin, Taurine, Pregabide
 - GABA Antagonist \rightarrow Bicuculline, Gabazine
 - BZD-R Agonist \rightarrow Benzodiazepens
 - \hookrightarrow Facilitate GABA actⁿ & \uparrow frequency of opening
 - BZD Antagonis - Flumazenil
 - BZD Inverse Agonist \rightarrow B-Carboline (Dmcm)
 - Picrotoxin (Non competitive GABA Antagonist)
 - Barbiturates (Allosteric GABA Agonist)
 - \hookrightarrow prolong GABA action & open Cl⁻ channel
 - (+) Neurosteroides \rightarrow Alphaxalone (Steroidal Anesthetic) pregnanolone, Alloprenandone
 - \hookrightarrow They facilitate GABA actⁿs \uparrow channel opening time and Frequency
- | | | |
|--|---|-------------------------------|
| # α_1 - Sedative action | } | - BZD action
- (Histidine) |
| # α_2 - Anxiolytic action | | |
| # α_3 - anxiolytic & anticonvulsant | | |
| # α_5 - learning & memory (Amnesia) | | |

GABA RECEPTOR PHARMACOLOGY

GABA_B

→ Metabotropic Receptor - G_{i/o}PCR (↓cAMP Pathway)




- # GABA_{B(1)} Agonist - GABA, Baclofen
- # Antagonist - CGP 35348, CGPS4626

- # Distribution - CNS & PNS
- # Effect - IPSP, G_iPCR - ↓cAMP, ↑K⁺ & ↓Ca²⁺ conductⁿ
- # Action → 1^o site is spinal cord (depress both poly synaptic & monosynaptic reflex), usefull in pain management, spinal injury, multiple Sclerosis, central muscle relaxant

GABA_A Receptor

- # Ionotropic / L.G.I.C. - Cl⁻ ion channel → Hyperpolarizatⁿ
- # Pentameric transmembrane Receptor
- # GABA_AR - 5 P subunit
- # Lake of modulatiⁿ by BZD, Barbiturates



- # Distribution - Spinal cord & Retina
- # GABA_A Agonist - GABA, TACA
- # Partial Agonist → muscimol, CACA (4-Amino-2-butanoic acid)
- # Antagonist - PicROTOXIN, TPMPA
Tetrahydro pyridine methy phosphonic acid


- # Role of GABA (GABA_AR)
- # Sedative & Hypnotics
- # Anxiolytic
- # Schizophrenia - VTA - α₃ GABA_A (BZD)
- # Depression - α₂ GABA_A - BZD
Anxiolytic action
mood regulation
- # Cognitive behavioral - α₅ GABA_A - BZD
- # Stroke - α₅ - GABA_A (BZD)
- # Anti epileptic action

DOPAMINE RECEPTOR PHARMACOLOGY

Dopamine → Predominant catecholamine NT present in the CNS. Dopaminergic neurons regulate the motor function, locomotion, learning & memory, mood/behavioral, endocrine function, & food intake in CNS. In PNS, it regulates the CVS, GI motility, Renal function, catecholamine release

RECEPTORS - 1 D₁ like (D₁, D₅ R) - G_sPCR (excitatory)
 2 D₂ like (D₂, D₃, D₄ R) - G_iPCR (inhibitory)

Pathways - # Nigrostriatal Pathway (motor control)
 # Mesolimbic/mesocortical Pathways (behavioral)
 # Tuberohypophysial Pathways (endocrine control)



	Location	Signaling	Agonist	Antagonist	Function
<u>D₁R</u>	Striatum, limbic system, Thalamus, Hypothalamus, Smooth muscles	G _s PCR 	Dopamine Apomorphine Fenoldopam SKF 38393	SCH 23390 SCH 39166 Butaclamol (Inverse Ag)	Renal Vasodilation + Inotropic, Cognitive function, (+) NMDA R
D ₅ R	Mid brain, Hippocampus, Thalamus, Cerebral cortex, striatum, vascular	-G _s PCR	Apomorphine Fenoldopam SKF 38393	SCH 23390 Butaclamol	↓ AT ₂ Expression & Vascular Proliferation
<u>D₂R</u>	Pituitary gland, striatum, Hypothalamus	G _i PCR 	Bromocriptin Pergolide Ropinirole	Haloperidol Sulpride Risperidone	Locomotion, learning & memory, Attention, motor function, sleep ↓ Prolactin ↑ GH, CTZ (Emesis) Reward
D ₃ R	Limbic System, Cortex, Hypothalamus	G _i PCR	Pramipexol Rotigotine Quinpirole	- " -	presynaptic (↓ dopaminergic) Locomotion, cognition, sleep
D ₄ R	Cortex, limbic system, Amygdala	G _i PCR		Nafadotride	Cognition, impulse control, sleep, reproductive behavior,

ANTI-ANXIETY DRUGS

ANXIETY :- An Emotional state, unpleasant in nature, associated with uneasiness, discomfort, concern or fear about some defined or undefined future threats.

Somatic Symptoms -

- # Anorexia
- # Breathlessness
- # Palpitation
- # Sweating
- # Paresthesia (Pins & needles Sensation)

Treatments when excessive & disproportionate to the situation

Some depressed and Psychotic patients also feel Anxiety.

↳ Cardiac Neurosis → Fear to heart disease → palpitation, Pericardial pain.

↳ GI Neurosis → Reflex & Acidity

↳ Social Anxiety → Fear to other thought

- ↳ OCD - Obsessive-Compulsive disorder
- ↳ Post Traumatic Stress disorder (PTSD)
- ↳ Phobia

ANXIOLYTIC DRUGS

- # CNS depressant drugs → Control Symptoms
 - ↳ have no effects on Schizophrenia
 - ↳ Do not produce Extra pyramidal Side effects
 - ↳ have anticonvulsant property
 - ↳ Produce Physical dependence
- BZDs - Diazepam, Oxazepam, Alprazolam, Clonazepam
 - Azapirone - Buspirone, Gepirone, Isipirone
 - Sed. Anti-H₁ → Hydroxyzine
 - B-blocker - Propranolol

DEPRESSION ☹️

↳ Depression is a state of "Low Mood" that affects the person's "mood", "Feelings", "Behaviour", & "Thought"

↳ Significant risk of Suicidal death

PAST ↔ Present ↔ Future

SYMPTOMS :->

Emotional Symptoms -

- ↳ Misery, Apathy, & pessimism
- ↳ Low Self Esteem:- Guilty, Inadequacy & Ugliness
- ↳ Indecisiveness, Loss of motivation

Biological Symptoms:-

- ↳ Retardatⁿ of thought & action
- ↳ Loss of libido, Sleep disturbance, ↓ Appetite

TYPES :-

1. Major Depression - Severe symptoms
2. Atypical Depression - Subtype of Major Depression, and can be treated with medicine
3. Dysthymia (Recurrent, mild depression)
4. Seasonal Affective Disorder (SAD) - Reduced day-light hour in winter may increase the depressive symptoms in some people.

I UNIPOLAR DEPRESSIVE SYNDROME :- Mood swings are always in same direction.

→ Associated with stressful life events. Common symptoms are anxiety and agitation. Reactive Depression (75%)

→ Endogenous Depression (25%) - Familial pattern

II. BIPOLAR DEPRESSION - Dep. alternates with Mania

- ↳ Usually appears in early adult life
- ↳ Strong hereditary tendency.

ETIOLOGY - Stressful life Events, Medical Treatment, Psychiatric Syndrome, Genetic

PATHOPHYSIOLOGY:-

Monoamine Hypothesis - Proposed by "Schildkraut" in 1965. - "Depression is caused by functional deficit of Monoamine Transmitters (N-Ad, 5HT) at certain site of Brain"

Neuroendocrine mechanism

Hypothalamus \xrightarrow{CRH} Pituitary \xrightarrow{ACTH} Cortisole Sec.

Neuroinflammation & Immune mechanism

DRUG TREATMENTS -

1. Tricyclic Antidepressants (TCAs) -
 - # NA & 5HT Reuptake inhibitor - Imipramine, Doxepine, Amitriptyline, Clomipramine, Trimipramine
 - # NA reuptake inhibitors - Desipramine, Nortriptyline
2. SSRI - Fluoxetine, Fluvoxamine, Paroxetine
3. SNRI - Venlafaxine, Duloxetine
4. MAO-A inhibitor - Moclobemide, corgyline
5. Atypical Antidepressant - Trazodone, Mianserin, Mirtazapine, Bupropione, Amoxapine

ANTI-DEPRESSANT DRUGS

MAO (Mono-Amine-Oxidase) - Mitochondrial Enzyme responsible for oxidative deamination of Biogenic Amines (NA, Adr, DA, & 5HT)

MAO-A → NA & Serotonin ; MAO-B → Phenylethylamine

Dopamine metabolised by both MAO-A & MAO-B

MAO-A : → Peripheral Ad.-neuron, Intestinal mucosa & human placenta, & Liver

↳ INHIBITORS → Clorgyline & Moclobemide

MAO-B → Brain, Platelets & Liver

↳ INHIBITOR → Selegiline

Isoniazid & Iproniazid (1951) - Anti-TB drugs
↓ degradatⁿ of biogenic amine → ↑ Mood

1960s → Phenzine, Isocarboxazide (INH Derv.)
Tranylcypromine (Amphetamine derv.)

↓
They are Non-selective MAO-Inhibitor, more toxic

ADR - Postural hypotension, Restlessness, insomnia
Sexual dysfunction,

CHEESE REACTION : → MAO Inhibitors with Tyramine, dopa containing food/products (cheese, beer, fish, meat)
Cause → "Hypertensive Crisis"

- # Similar reaction occurs with ephedrine, TCAs, SSRIs, SNRIs,
- # Hallucinatⁿ & Atropine poisoning like symptoms occurs with - Alcohol, sed.-Anti H₁, Barbiturates & opioids → ↓ Res.
- # MAOIs + Pethidine → fever, Sweating, Excitatⁿ, delirium, convulsion, Res. depression due to over productⁿ of nor-pethidine

Moclobemide Pharmacology

MOA - Reversible MAO-A Inhibitor (Short duratⁿ of action)

↳ Restriction of dietary is not required, because tyramine is able to displace from the enzyme

It has lack to anticholinergic, sedative, Cognitive, CVS, psychomotor side effects unlike TCAs.

Antidepressant alternative to older & heart patients. And in Social Phobia

ADR = Nausea, dizziness, headache, Insomnia
Rarely excitement & Liver damage


Contraindicated with - Alcohol, Pethidine, SSRIs & TCAs

TRICYCLIC ANTI-DEPRESSANT

NA + 5HT Reuptake Inhibitors →

Imipramine, Trimipramine, Clomipramine,
Amitriptyline, Doxepin, Dothiepin,

NA-Reuptake Inhibitors → Desipramine, Nortriptyline



→ "Imipramine" - 1958

→ CPZ derivative

→ Beneficial in depression not
in psychosis

TCA's: 1st Gen. Antidepressant

↳ # NA & 5HT Reuptake Inhibitor (NET & SERT)
Also act on cholinergic, Adr. & histaminergic R

Pharmacological Action: →

① CNS - A) In Normal Person → (+) Anxiety

B) In-Depressed Patient → Acute Sedative effect,
after 2-3 weeks of continuous treatment,
the mood is gradually elevated, Patients become more
communicative in surrounding environment.

TCA's → Not euphoriant only antidepressant.

↳ At low dose → ↓ REM sleep (Hypnotic like)

↳ At high dose → disturbed sleep cycle

↳ ↓ Seizure threshold → (+) Convulsion

↳ Clomipramine & Bupropion

↳ overdose → Respiratory depression

2) ANS - # Anticholinergic → Constipation, Blurred vision, etc.

Potentiate NA action, also have- α_1 -blocking actn

Antihistaminergic → Amitriptyline, Doxepin, Trimipramine

3) CVS → Tachycardia, Postural hypotension, Arrhythmia

Tolerance & Dependence -

Tolerance to anticholinergic & hypotensive effects

Addiction is rare, physical dependence may occur

P'KINETIC → Good Oral Abs, $V_d = \sim 20L/kg$, Metabolised - Liver

$t_{1/2} = 16-20h$, Therap. range → 50-200 ng/ml

ADR - # Anticholinergic

Antihistaminic - Sedation

↑ Appetite & wt gain

Seizure # CVS disorder

Dysphoria & Mania (Switch Over) # Sexual disturb.

INTERACTION → # Potentiate Sympathomimetic Action

+ Alcohol, Anti-H₁ → ↑↑ CNS depression

Protein binding displacement with Phenytoin, Aspirin, etc

Phenobarbitone, Carbamazepine → ↑ Metabolism of TCA's

SSRIs → ↓ Metabolism TCA's → Toxic action

Due to Anticholinergic → ↓ Absorption of own & other

+ MAO-Is → "Hypertensive Crises"

Use - Antidepressant, Neuropathic pain, ADHD, Pruritis
Premature Ejaculation, Migrain, Smoke Cessation



SELECTIVE SEROTONIN REUPTAKE INHIBITORS

SSRIs → Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Dapoxetine, Escitalopram

- # 1980s → 2nd Gen Antidepressant drugs → SSRIs & SNRIs
- # They have minimal side effects unlike the TCAs.
 - ↳ cholinergic, histaminergic, CVS, neurological ADR
 - ↳ low safety of margin
 - ↳ Incomplete response or no response to TCAs

MOA : → SSRIs → ↓ SHT Reuptake (SERT)
SNRIs → ↓ SHT (SERT) & NA (NET) Reuptake

- # Their efficacy is higher than TCAs & RIMAs
- # More safer at overdose & better tolerability

"SSRIs"

- # 1st-line drug for depression
- # Also used in Anxiety, Phobia, Panic, OCD & Related disorder
- # **ADR** = GI disturbance - Nausea (due to (+)5HT₃R), loose motion (due to SHT uptake blockade & +5HT₂R), sexual (ejaculation) problem, Insomnia, Nervousness, anorexia, dyskinesia, headache.
 - > Epistaxis & Ecchymosis (due to platelet dysfunction)

AND SEROTONIN & NORADRENALE REUPTAKE INHIBITORS

SNRIs - Venlafaxine, Desvenlafaxine, Duloxetine

INTERACTION - + NSAIDs → ↑ Gastric blood loss

- # SSRIs (Enz Inhibitors) - ↓ metabolism of TCAs, Haloperidol, warfarin, β-blockers, etc
- # + MAOIs, Tramadol, Pethidine → (+) "Serotonin Syndrome" like agitatⁿ, restlessness, rigidity, hyperthermia, delirium, sweating & twitching

"SNRIs" (Novel Antidepressant)

- # Similar effective as TCAs, but lesser side effects
- # **Faster onset of action**
- # **Uses** - Antidepressant, mood changes in menopausal Syndrome, Social Anxiety & Eating disorder
- # **ADR** - Nausea, Vomiting, Sweating, anxiety, Dizziness, Impotence, withdrawal symptoms after discontinue
- ♦♦ Duloxetine → Little Sedative & antimuscarinic action

ATYPICAL ANTI-DEPRESSANT DRUGS

DRUGS - Trazadone, Mianserin, Mirtazapine, Bupropione, Amoxapine, Tianeptin, Amineptine

TRAZADONE - Block SHT uptake, Prominent α -R & Weak SHT₂R blocker (Metabolite strong SHT₂R blocker)

Modest Antidepressant effect

ADR - Sedative (but not anticholinergic), ↓HR
Nausea, Priapism (Painful Penile erection - α_1 R)
Postural hypotension (α_1 R blockade)

MIANSERIN → Block α_2 R → ↑NA Release

Also block SHT₂, SHT_{1c}, & H₁ Receptor

Antidepressant, Sedative → in Anxiety and Panic Attack.

ADR → seizure in overdose, Blood dyscrasias, Liver dysfunction.

MIRTAZAPINE → Antidepressant by blocking α_2 R present presynaptic NA-neuron & hetero (Serotonergic) neurons. → ↑NA & SHT Release
→ (+) SHT₁R & block SHT₂ & SHT₃ receptors
→ Also known - Noradrenergic-Serotonergic Antidepressant (NaSSA)

→ H₁ blocker (Sedative), mild anticholinergic

use → in Depression with insomnia

ADR - ↑ Appetite & weight gain.

BUPROPIONE → DA & NA uptake inhibitor, → Excitant
↳ Amphetamine like metabolite → ↑ presynaptic release of DA & NA

Sustained release → Smoking Cessation with Nicotine patch
↑ Dopaminergic Reward function

ADR - Insomnia, Dry mouth, Agitation, nausea.
Seizure (in overdose)

Contraindicated - in Eating disorder & Bipolar illness.

use → Along with SSRIs

AMOXAPINE → Tetracyclic compound

→ block D₂R & NA uptake

→ Antidepressant + Neuroleptic properties

- ADR → Seizure & EPS

TIANEPTIN : → Antidepressant showing increase the uptake of SHT (neither Sedative nor Stimulant)

→ Effective in Anxio-depressive patient with psychomimetic symptoms.

- ADR → Dry mouth, Epigastric pain, Flatulence, drowsiness, Insomnia, Tremor, body aches



SCHIZOPHRENIA

- ↳ Schizophrenia is a chronic & severe mental disorder that is imp form of psychiatric illness affects how a person thinks, feels, & Behaves.
- ↳ They have lost touch with reality.

A. Positive Symptoms - "Psychotic Behave"

- # Hallucinations # Delusions # Thought disorder
- # Abnormal behaviour # Movement disorder

B. Negative Symptoms

- # Flattening of emotional response
- # Withdrawal from social contact
- # Reduced feeling of pleasure

C. Cognitive Symptoms

- # Reduced Cognitive Function (Attention, learn, memory)

ETIOPATHOGENESIS

1. Genetics → Family history ↑ the risk

- ↳ Neuregulin-1 gene → Neuronal synaps & plasticity
→ NMDA Receptor Expression
- ↳ gene for d-amino acid oxidase (DAAO) → D-Serine
Allosteric modulator of NMDA Receptor

2. Environmental Factors -

- ↳ Maternal viral infection - ↓ Neuronal development
- ↳ Cannabis consumption
- ↳ Drug Addiction
- ↳ Environmental toxins

NEUROCHEMICAL THEORIES - Pathophysiology

1. Dopamine Theory - Carlson proposed Dopamine theory & got Nobel prize in 2000.
⇒ ↑ Dopaminergic (D₂) pathway may responsible for psychotic behaviour.
2. Glutamate Theory - ↓ Glutaminergic pathway
3. Serotonin Theory - ↑ Serotonergic pathway
Serotonergic — Dopaminergic

DRUG MANAGEMENT

1. Neuroleptics (D₂ Antagonist) = Typical
 - A. Phenothiazine - Chlorpromazine, Thioridazine, Fluphenazine
 - B. Butyrophenone - Haloperidol, Trifluperidol
 - C. Thioxanthine - flupenthixol
2. Atypical Antipsychotic Drugs
 - Clazopine, Risperidone, Olanzapine
 - Ziprasidone, Zoltepine,

NEUROLEPTICS (ANTI PSYCHOTIC DRUGS)

- ↳ Chlorpromazine, Triflupromazine, Thioridazine
- ↳ Trifluoperazine, Fluphenazine (phenothiazines)
- ↳ Haloperidol, Trifluperidol, Penfluridol (Butyrophenones)
- ↳ Flupenthixol (Thioxanthine)

MOA - D₂ Blockers (Limbic System & mesocortical)

PHARMACOLOGY OF CPZ

DCNS - # In non psychotic → Paucity of thought, psychomotor slowing, emotional quietening "Neuroleptic Syndrome" & produce Extrapyramidal motor side effect

In psychotic → Control Psychosis behaviour

- ↳ Aggressiveness ↳ Agitation
- ↳ Disturbed thought ↳ Anxiety
- ↳ Hyperactivity ↳ Hallucination

CPZ & Thioridazine → more Sedative action

Intelligence and performance - Unaffected

CPZ ↓ Seizure threshold

CPZ at high dose - ↓ Body temp.

Other vital function → not affected (at therap. dose)

CPZ, Haloperidol → Antiemetic (CT₂)
Triflupromazine


2) ANS - Anti-α and Anticholinergic (M₁)

α blocking → CPZ = Triflupromazine = Thioridazine
↳ Fluphenazine > Haloperidol > Trifluoperazine
↳ Pimazole * more potent (D₂) - less α blocking

Anticholinergic - Thioridazine > CPZ > Triflupromazine > Trifluoperazine = Haloperidol

3) Local Anesthetic → CPZ (mem. stab. actⁿ)

4) CVS → ↓ BP & Reflex Tachycardia
at high dose → myocardial depression and prolonging QT & suppress T wave

5) Endocrine → ↑ prolactin Release 
this may cause Galactorrhoea and Gynaecomastia

CPZ → ↓ GnH, GH, ADH release & ↓ ACTH response
↳ impaired Glucose tolerance → + Diabetes

Tolerance & Dependence

Tolerance to the sedative & hypnotic action develops within days or weeks, not for psychotic action.



NEUROLEPTICS (ANTI PSYCHOTIC DRUGS)

Pharmacokinetics - CPZ

- # Oral Abs \rightarrow unpredictable, BA = low, So IM & IV
- # Highly tissue (brain) protein binding ($V_d = 204 \text{ kg}$)
- # Metabolized by CYP2D6 # $t_{1/2} = 18-30 \text{ h}$
- # excreted through urine & bile for months after discontinue the drug

* EPS Effect = Haloperidol = Trifluoperazine
> Triflupromazine > CPZ > Thioridazine

- 1) Triflupromazine \rightarrow more potent than CPZ, Antiemetic, muscle dystonia in children
- 2) Thioridazine - Low potency, marked anticholinergic, low EPS, Arrhythmia, impaired sexual function & eye damage
- 3) Trifluoperazine & Fluphenazine \rightarrow high potent, less ANS action, marked EPS & dyskinesia
- 4) Haloperidol \rightarrow most commonly used. potent antipsychotic similar piperazine deriv., few ANS acts preferred for acute Schizophrenia, Huntington's disease and Gilles de la Tourette's Syndrome

5) Flupenthixol - less sedative than CPZ used in Schizophrenia particularly in withdrawn & apathetic patient

6) Pimozide - Selective D_2 blocker not having ANS action. used for maintenance used in Gilles de la Tourette's Syndrome

ATYPICAL ANTIPSYCHOTIC DRUG

- ↳ 2nd Generation newer antipsychotic drugs having minimal D₂ blocking activity but potent SHT₂ Antagonistic Activity.
- ↳ Drugs → Clozapine, Olanzapine, Risperidone, Quetiapine, Aripiprazole, Ziprasidone

1. CLOZAPINE

- # Minimal D₂ blocking → low EPS effects
- # Mainly → SHT₂ Antagonistic action
- # Other → D₄ blocking, Anticholinergic (M₁) & Antihistaminic (H₁) action
- # Control both +ve & -ve Schizophrenia
- # ADR - Agranulocytosis, Metabolic dysfunction (Hyperlipidemia, weight gain, Diabetes), Seizure may be induced, Sedation, unstable BP, Tachycardia, Myocarditis, Urinary incontinence.
- # Use - Reserve for Refractive Schizophrenia
• Also improve the cognitive function

2. Aripiprazole

- # Partial D₂ & SHT_{1A} Agonist & SHT₂ Antagonist
- # Improve cognition & used in Schizophrenia (+/-)
- # May cause Hyperglycemia & ↑ QT interval
- # Also helpful in resistant depression & bipolar

3. Ziprasidone

- # Antagonistic activity on D₂, SHT_{2A/2C}, H₁ & α₁
- # Agonist on SHT_{1A} # Antagonist on SHT_{1D}
- # ↓ reuptake of SHT & NA (Antidepressant and anxiolytic action)
- # used in Schizophrenia & Mania
- # ADR - Sedation, Hypotension, weight gain, Hyperglycemia, "Low EPS"

4. Risperidone

- # D₂, SHT₂-blockade → Antipsychotic Actⁿ
- # α & H₁ blockade → Hypotension & Sedation
- # More potent D₂ blocker than clozapine but EPS shows at high dose > 6mg/day
- # ADR → ↑ Prolactin, EPS
→ Less Epileptogenic than clozapine
↳ weight gain, Diabetes may precipitate
- # Use - 1st line drugs for Schizophrenia


DRUG USED IN MANIA & BIPOLAR DISORDER

- ↳ Lithium Carbonate
- ↳ Antiepilepsy - Sod. Valproate, Carbamazepine, Lamotrigazine
- ↳ Antipsychotic → Olanzapine, Risperidone, Aripiprazole

LITHIUM CARBONATE

- ↳ Monovalent cation. In 1949, it was found to have Sedative action in animals and beneficial effects in manic patients

MOA :-



D CNS - Mood Stabilizer in Bipolar disorder

- Suppress the manic episode, taking 1-2 weeks
- Markedly reduce sleeptime in manic patient
- # Li⁺ - Replace the Na⁺ and distributed equally and affect the ionic flux.
- # ↓ the presynaptic release of NA and DA without affecting SHT



2) Other action - ↓ action of ADH and may cause diabetes insipidus.

→ Insulin-like action on Glucose metabolism

PKINETIC → Orally well absorbed but neither protein bound nor metabolised

→ uniform distribution - plasma = CSF

→ Vd = 0.84/kg

→ Excreted through urine, 80% are reabsorbed

→ Narrow margin of Safety, 0.5-0.8 mEq/L for maintenance therapy

→ > 1.5 mEq/L → Toxic Action

ADR : → Nausea, Vomiting, mild diarrhoea,

Thirst, Polyuria, Tremor, CNS Toxicity

(Tremor, rigidity, Ataxia, Motor inco-ordination, mental confusion, slurred speech)

→ 2 mEq/L → muscle twitching, convulsion, etc

↳ Treatment → Osmotic diuresis, NaHCO₃

Interaction # Diuretics → ↑ Li⁺ reabsorption

NSAIDs, ACEIs → Li⁺ retention

Li⁺ → ↓ pressor response of NA

Li⁺ → ↑ Sulfonyl urea & insulin action

Uses → Acute mania & Bipolar disorder

HALLUCINOGEN (PSYCHOTOMIMETICS)

INDOLE AMINE :- "Lysergic acid diethylamide (LSD);
Lysergic acid amide, Psilocybin, Harmine, Bufotenin

PHENYLALKYL AMINE → Mescaline, Ecstasy, Yaba

ARYLCYCLOHEXYL AMINE → "Phencyclidine"

CANNABINOID - "Tetrahydrocannabinol"

✓ "LSD"

- # Synthesized by "Hofmann" (1938) from "Ergot" and himself feel hallucinogenic effect.
- # Most potent - 25-50 ug produces all effects.
- # Shows mental effects and stimulates centrally sympathetic system
- # MOA = SHT₂ Receptor Agonist

"CANNABINOIDS"

- ↳ "Cannabis indica" (Marijuana)
- ↳ "Bhang", "Ganja", "Charas" - use "worldwide"
- ↳ Cannabis is the drug of abuse having the lowest acute toxicity, even habitual use is not associated with serious neurotoxicity or damage to any other organ toxicity.

Thought, Personalities, and Psychiatric problem are more common in cannabis user.

Young → Amotivational Syndrome

Cannabinoid Receptor - CB₁R (CNS)
→ (+) - CB₂R (Peripheral)

"Anandamide" (Ethanamide of arachidonic acid)

Actions - # Anti-inflammatory - Analgesic

Antiemetic - Cancer chemo-induced, "Dabilone" & "dronabilone"

To relieve anxiety & migraine

↓ IOP - Glaucoma

Bronchodilators (Asthma)

Appetite Stimulant

↳ Hallucinogens (Marijuana) produce dream like state with disorientation.

↳ Produce tolerance & Psychological dependence.

CNS-STIMULANTS

The drug which stimulate the CNS or improve specific function of Brain

1. **CONVULSANT** - Strychnine, Picrotoxin, Bicuculline, Pentylenetetrazole (PTZ)
2. **ANALEPTIC** - Doxapram
3. **PSYCHOSTIMULANT** - Amphetamine, Methylphenidate, Atomoxetine, Modafinil, Armodafinil, Cocain, Caffeine

CONVULSANT

1. Strychnine → alkaloid - "Strychnos nux-vomica"
→ ↓ Glycine transmission
2. Picrotoxin → obtain from "fish-berries" (*Anamixta Cocylus*) → GABA_AR allosteric antagonist
3. PTZ → ↓ Depolarize the CNS neurons
→ ↓ GABA Transmission

ANALEPTIC (RESPIRATORY STIMULANT)

Restrictive used in Coma or fainting at Subconvulsive dose, (Margin of safety in narrow)

1. **Doxapram** → iv inj. in fainting, barbiturate poisoning ventilatory failure in COPD, suffocation, etc.

PSYCHOSTIMULANT

1. **Amphetamine** → Sympathetic stimulation
2. **Methylphenidate** → ↑ release of NA & DA Centrally
→ used in ADHD in children
→ used in Narcolepsy (Adult)
3. **Atomoxetine** - NA reuptake inhibitor, Not (+) CNS, but improve attention & Behaviour in ADHD
4. **Modafinil** → Newer psychostimulant is popular with night-shift (Call Centre) workers & others.
→ Improve alertness & keep awake.
→ ↓ NA & DA uptake, Modulate GABA & Glutamate
→ Used in - day time sleepiness due to narcolepsy, Sleep-apnoea syndrome, Shift-work disorder.
↓ Cocain withdrawal symptoms & Dependence
5. **Caffeine** - Xanthene derivative → (+) CNS
MOA → # PDE-Inhibitor # Antagonise Adenosine R
Antagonise BZD_R, # ↑ Ca²⁺ signaling
use → Combination → Analgesics, Migrain
→ Apnoea in infant alternate to theophylline
→ CNS stimulant

ALZHEIMER'S DISEASE (AD)

AD is the commonest progressive, dementing, neurodegenerative disease in elderly (>65y)

"Alois Alzheimer", a German Scientist described symptoms & pathology - "Neuronal loss", "Plaques",

Δ Neurofibrillary tangles

Major Affected Area → Cerebral Cortex

Clinical Sign & Symptoms :-

1. Mild → memory loss, language problem, behavioral changes, Judgement impairment

2. Moderate: - Behavioral/Personality changes, unable to learn & recall new info., long-term memory loss, Confusion, Aggression

3. Severe: → + motor disturbance

* Aphasia - Disturbance in language function

* Apraxia - Impaired motor function

* Agnosia - Inability to recognise name of objects

* Executive Functioning - Inability to think abstractly

Risk Factors - ① Aging >65y ⇒ Progressive neuronal loss

② Hypertension ③ Diabetes ④ Hyperlipidemia

⑤ Down Syndrome ⑥ Smoking & Alcohol

6) Genetic - mutation on - # Amyloid Precursor Proteins (APP)
Presenilin gene (PSEN1 & PSEN2)

β-secretase (BACE1)

γ-secretase # ε4 allele of apolipoprotein E (APO-E)

Pathophysiology -

1. Neuronal Damage - loss of neurons & synaps, cerebral atrophy, ↓ Cholinergic neurone, imbalance of Glutamatergic neurons.

2. Genetic mutation

3. Disposition of β-Amyloid protein - resulting in Neuritic "Senile" Plaque - Neurotoxic

4. Neurofibrillary Tangles - are filamentous collection of neurofilaments & microtubules within the cytoplasm of neuron

Management -

1. Nutrients - ω-3-fatty acid, Curcumin, vit E, Ginkgo

2. Cognitive Enhancers: -

a. Anti-cholinesterase - Rivastigmine, Donepezil, Galantamine

b. Glutamate Antagonist - Memantine

c. Others - Piracetam, Citicoline, Pyritinol, Dihydroergotoxin, Ginkgo biloba

ANTI-ALZHEIMER'S DRUGS

Cognition Enhancers / Cerebroactive Drugs

A) CHOLINERGIC ACTIVATORS (ChE Inhibitors)

↳ Rivastigmine, Donepezil, Galantamine, Tacrine

RIVASTIGMINE → Carbamate deriv. of physostigmine &

↳ Inhibits both AchE & BuChE, but is more selective for G₁ isoform of AchE that predominant in Brain.

↳ highly lipid soluble — easily cross BBB

↳ ↑ cholinergic transmission in brain

↳ 3.8 point improvement in Alzheimer Disease Assessment Scale (ADAS-cog)

↳ Other symptoms apathy, delusion, agitation, and hallucination are also improved

↳ No/min. peripheral side effects

↳ Used in mild to moderate AD

B) NMDA ANTAGONIST → "MEMANTINE"

↳ Newer NMDA-receptor blocker related to Amantadine

↳ Block the excitotoxicity of Glutamate transmission

↳ use — moderate to severe AD (better tolerated)

↳ Also effective in PD

↳ side effects — constipation, headache, tiredness, dizziness, & drowsiness

"PIRACETAM" — Cyclic GABA derivative but no GABA action, "Nootropic drug" — Improve the efficiency of higher telencephalic integrative activities.

↳ Reduce blood viscosity

↳ Improve cognitive impairment & dementia in elderly as well as mental retardation in children.

↳ In UK, approved for adjunctive treatment of cortical myoclonus

"PYRITINOL" (Pyritroxine) — 2 mole. of pyridoxine bind with disulphide bridge

↳ No Vit B₆ Activity

↳ ↑ Glucose transport in brain,

↳ ↑ regional blood flow in ischemic brain area.

"PIRIBEDIL" — Dopaminergic agonist

"CITICOLINE" — Derived from choline & cytidine that involved in synthesis of Lecithine

↳ Improve cerebral blood flow

↳ Indicated in impaired brain func. due to Ischemia, stroke, PD, & head injury.

GINKGO BIOWBA → Ginkgolide-B → PAF Antagonist
→ Improve blood flow

MORPHINE PHARMACOLOGY

MORPHINE is an alkaloid present in Opium (*Papaver somniferum*) & it is a phenanthrene derivative.

MOA - (+) Opioid Receptor (GiPCR) mainly μ R

PHARMACOLOGICAL ACTION -

1) CNS - Analgesia[#] \rightarrow # Visceral Pain is relieved better than Somatic pain

- # Nociceptive pain is relieved better than Neuropathic
- # Pain associated reaction are also relieved.
- # Modulate the pain pathway in spinal & Supra-spinal region by inhibiting Excitatory Transmitter

Sedation[#] - drowsiness - sleep - "Coma"

Euphoria[#], Respiratory depression - Death, Suppression of cough, Hypothermia in cold condⁿ, Depressed vasomotor Centre \rightarrow \downarrow BP

Stimulatory Actions \rightarrow # + CTZ \rightarrow Vomiting/nausea

- # (+) Edinger-Westphal nucleus of III nerve by \downarrow GABA -ergic interneuron \rightarrow Miosis
- # (+) Vagal Centre \rightarrow Bradycardia (\downarrow HR)

2) NEURO-ENDOCRINE ACTION = Modulate hypothalamic

- Pituitary function \rightarrow \downarrow FSH, LH, ACTH
 \uparrow Prolactin & GH
- \hookrightarrow Also \downarrow Sex hormone & Cortisol level

3) PERIPHERAL ACTION -

- a) CVS \rightarrow \hookrightarrow Vasodilation (due to histamine release)
 \hookrightarrow \downarrow vasomotor Centre \rightarrow \downarrow BP

b) GIT \rightarrow \downarrow GI motility - Antidiarrhoeal action.

c) Other Smooth muscle -

- # \uparrow Spasm of sphincter of Oddi \rightarrow \uparrow Intrahepatic pressure \rightarrow B. colic
- # \uparrow tone of Bladder & detrusor sphincter \rightarrow Urine urgency
- # Bronchoconstriction (due to histamine)

P'KINETIC \rightarrow unreliable oral abs., high 1st pass metabolism, oral BA = 25%, PB = 30%, widely distribution, small fraction of morphine enters Brain slowly, also cross placenta & affect foetus. [#] Metabolised by glucuronic conjugatⁿ & metabolite is more potent to μ R. Morphine-3-Glucuronide \rightarrow Neurotoxic excretⁿ through urine & Bile, $t_{1/2}$ = 2-3 h

ADR - # Sedative # Idiosyncrasy & Allergy # Apnoea in new born (Antidote - Naloxone 10 μ g/kg) # Dependence

Acute morphine poisoning \rightarrow Res. dep., Miosis (pinpoint) coma, Flaccidity, Fall in BP, Cyanosis, Shock

\hookrightarrow Antidote \rightarrow Naloxone (0.4-0.8 mg, iv)

Contraindication \rightarrow # Asthmatic patients # Infant

- # Pregnancy, # Hypotensive or Hypovolemic state
- # Head injury \rightarrow \uparrow CO₂, \uparrow Intracranial pressure, Acidosis, Sedatⁿ
- # Undiagnosed Acute abdominal pain

Use \rightarrow # As Analgesic # Anesthesia (Fentanyl)
of # Cough # Anxiety
Opioids # diarrhoea

